Centessa Pharmaceuticals (NASDAQ:CNTA) Given New $19.00 Price Target at Jefferies Financial Group

Centessa Pharmaceuticals (NASDAQ:CNTA) had its price objective increased by research analysts at Jefferies Financial Group from $13.00 to $19.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Jefferies Financial Group’s price target points to a potential upside of 30.40% from the company’s previous close.

A number of other brokerages have also recently commented on CNTA. BMO Capital Markets raised their target price on Centessa Pharmaceuticals from $15.00 to $20.00 and gave the company an “outperform” rating in a report on Monday. Morgan Stanley raised their price objective on shares of Centessa Pharmaceuticals from $8.00 to $11.00 and gave the company an “equal weight” rating in a research note on Friday, June 21st. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $14.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th.

Centessa Pharmaceuticals Trading Down 0.1 %

Shares of CNTA stock traded down $0.01 during trading hours on Wednesday, hitting $14.57. The company had a trading volume of 225,018 shares, compared to its average volume of 349,904. The company has a debt-to-equity ratio of 0.27, a current ratio of 13.29 and a quick ratio of 13.29. The stock has a market capitalization of $1.46 billion, a PE ratio of -10.29 and a beta of 1.44. The company’s fifty day moving average is $11.36 and its 200 day moving average is $10.39. Centessa Pharmaceuticals has a fifty-two week low of $5.15 and a fifty-two week high of $17.25.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Research analysts expect that Centessa Pharmaceuticals will post -1.61 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Gregory M. Weinhoff sold 12,198 shares of Centessa Pharmaceuticals stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $12.17, for a total value of $148,449.66. Following the completion of the transaction, the insider now owns 241,171 shares in the company, valued at approximately $2,935,051.07. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Gregory M. Weinhoff sold 12,198 shares of the stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $12.17, for a total value of $148,449.66. Following the transaction, the insider now owns 241,171 shares of the company’s stock, valued at $2,935,051.07. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Saurabh Saha sold 4,169 shares of Centessa Pharmaceuticals stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $12.32, for a total value of $51,362.08. Following the sale, the chief executive officer now directly owns 827,755 shares of the company’s stock, valued at $10,197,941.60. The disclosure for this sale can be found here. Insiders have sold a total of 41,873 shares of company stock worth $581,000 in the last quarter. 11.59% of the stock is owned by company insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in CNTA. Jump Financial LLC acquired a new position in Centessa Pharmaceuticals in the fourth quarter valued at $114,000. Trexquant Investment LP acquired a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at about $114,000. Franklin Resources Inc. grew its stake in Centessa Pharmaceuticals by 34.1% during the 4th quarter. Franklin Resources Inc. now owns 1,115,817 shares of the company’s stock worth $8,882,000 after buying an additional 283,469 shares during the last quarter. Platinum Investment Management Ltd. increased its position in Centessa Pharmaceuticals by 12.9% during the fourth quarter. Platinum Investment Management Ltd. now owns 381,083 shares of the company’s stock worth $3,033,000 after buying an additional 43,539 shares during the period. Finally, Octagon Capital Advisors LP increased its position in Centessa Pharmaceuticals by 333.2% during the fourth quarter. Octagon Capital Advisors LP now owns 2,060,100 shares of the company’s stock worth $16,398,000 after buying an additional 1,584,500 shares during the period. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.